DS
SNDX icon

DRW Securities’s Syndax Pharmaceuticals SNDX Stock Holding History

DRW Securities’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,135
Closed -$132K – 1598
2025
Q2 		$132K Buy
+14,135
New +$156K ﹤0.01% 1004
2018
Q3 		– Sell
-15,000
Closed -$105K – 91
2018
Q2 		$105K Buy
+15,000
New +$147K 0.01% 89

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

DRW Securities's SNDX Position: Q3 2025 in Review

DRW Securities sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 14,135 shares — an estimated $132K sold.

DRW Securities first reported a position in SNDX in Q2 2018 and held it in 2 quarters. The position peaked at $132K in Q2 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • DRW Securities reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • DRW Securities sold 14,135 Syndax Pharmaceuticals shares in Q3 2025, an estimated $132K.
  • DRW Securities first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • DRW Securities's Syndax Pharmaceuticals position peaked at $132K in Q2 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.